Why Biosimilars Matter: An Innovative Solution to Improve Patient Access

Chairperson:

Felix Keil¹

Speakers:

Mark McCamish,² Robin Foà,³ Karen Van Rassel⁴

1. Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna, Austria
2. Sandoz, Holzkirchen, Germany
3. Hematology, ‘Sapienza’ University, Rome, Italy
4. Lymphoma Coalition, Toronto, Ontario, Canada

Disclosure:

Mark McCamish is a full-time employee of Sandoz. Felix Keil has received honoraria from Sandoz and Roche, and was an investigator in the Sandoz-supported ASSIST-FL trial of the proposed biosimilar rituximab (GP2013). Robin Foà has served on advisory boards or on speaker’s bureaux for Roche, Genentech, Celgene, Janssen, Gilead, GSK, BMS, and Sandoz.

Acknowledgements:

Writing assistance was provided by Dr Lynda McEvoy, apothecom scopemedical Ltd.

Support:

The publication of this article was funded by Sandoz. The views and opinions expressed are those of the authors and not necessarily of Sandoz.

Citation:

EMJ Hema. 2015;3[1]:47-53. DOI/10.33590/emjhematol/10311696. https://doi.org/10.33590/emjhematol/10311696.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.